LA JOLLA, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the development and application ...
A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides ...
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical util
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 22, 2025 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of cell-based liquid biopsy technology, ann ...
Marija Balic, MD, discusses how circulating tumor DNA assays for molecular residual disease detection have evolved in recent ...
In this GEN webinar, DNA synthesis experts Michael Junkin, PhD, and Brittany Enzmann, PhD, will provide an exclusive first look at Elegen’s GEN II Cell-Free DNA production platform that combines ...
Menarini Silicon Biosystems, a pioneer of cell-based liquid biopsy technology, announced today the publication in Clinical ...
Findings from a study on the utility of ultrasensitive circulating tumor DNA (ctDNA) as a predictive biomarker for patients ...
Biomarker Therapy in 2025: More Lung Cancer Options, Competition in New Drug Classes, ctDNA Advances
This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...
Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback